Dr Lal PathLabs

Diagnostics firm reports profit decline due to prior-year tax benefit, while revenue growth remains strong on higher sample volumes and improved test mix

Consolidated net profit fell to 1.31 billion rupees ($13.8 million) in the quarter ended March, from 1.55 billion rupees a year earlier

After a three-year strategic pause, diagnostics firm is unlocking its balance-sheet capacity look for growth-boosting acquisitions

After a three-year strategic pause, diagnostics firm is unlocking its balance-sheet capacity look for growth-boosting acquisitions

Diagnostics major reports a one-time charge linked to new labour codes even as revenue rose over 10% on higher sample volumes and network expansion

The ​country's largest diagnostics firm by revenue took up a one-time charge worth ₹30.1 crore linked to India's new labour codes

The ​country's largest diagnostics firm by revenue took up a one-time charge worth ₹30.1 crore linked to India's new labour codes

Dr Lal PathLabs is focusing on innovation, including new wellness packages and high-end, super-speciality tests, with a focus on capturing prescription shares

Diagnostic chains are expanding laboratories, integrated centres and collection networks as demand grows for preventive, genomics-led and precision testing across India

Technical charts show Escorts, Hudco, Dr Lal PathLabs, Force Motors and Godrej Consumer were trading above the higher-end of the Bollinger Bands on the daily scale; and can potentially rally up to 23%

Diagnostics chain declares ₹7 per share interim dividend, 1:1 bonus issue

Domestic brokerage firm Nuvama analysts forecast a modest sequential slowdown but a healthy ~17 per cent year-on-year (Y-o-Y) Ebitda growth, led by hospitals and diagnostics.

Dr. Lal Path Labs shares rose 3.2 per cent on Wednesday, after it became the first laboratory in the country to adopt a deep learning-based AI module to detect lymph node metastas

Bank of Baroda, Concor, HDFC Asset Management Company, and 22 others will be in focus today as they will trade ex-date on Friday, June 6, 2025

Abbott India, Aurobindo Pharma, Cipla, Dr Lal PathLabs and Torrent Pharma flag caution signals on technical charts; here are the key levels to watch out for.

The company's revenue from operations also rose to Rs 603 crore in Q4FY25, a 10.5 per cent Y-o-Y growth from Rs 545 crore reported in Q4FY24

The company's consolidated net profit jumped 83.2 per cent year-on-year to Rs 1.55 billion (about $18 million) in the quarter ended March 31

As for Suburban Diagnostics, an arm of Dr Lal Pathlabs, revenue growth was 9.2 per cent in Q3

The company's consolidated net profit rose to Rs 96.7 crore ($11.2 million) in the three months to Dec. 31, from Rs 81.3 crore a year earlier, but fell short of analysts' estimate of Rs 97.69 crore

Apollo Hospitals, Vijaya Diagnostic and Narayana Hrudayalaya have given a fresh breakout on the daily scale. Charts show that these 5 healthcare related shares can rally up to 11 per cent.